FROM DAILY MAIL: The rise of GLP-1 receptor agonists, including Ozempic and Mounjaro, being used for weight loss has been linked to a higher risk of self-harming thoughts and behaviour.
The Therapeutic Goods Administration, Australia’s medicine regulator, issued a safety warning regarding drugs that activate GLP-1, the hormone which regulates blood sugar and appetite, on Monday.
The class of drugs is largely intended to treat type two diabetes, but have become popular for their weight loss side effects.
On Monday, the TGA announced a search of its Database of Adverse Event Notifications on September 23 retrieved 85 reports of GLP-1 RAs linked to a decline in mental health.
Of those reports, 72 were for suicidal ideation, six were for depression related suicide, four were for suicide attempts, two were for suicide, and one was due to ideation of self-injury.
An investigation has now been launched by an independent expert group, the Advisory Committee on Medicines, which previously found that there was not enough evidence to link GLP-1 medications to suicidal ideation or behaviors.
There are fresh safety warnings for users of injectable weight loss drugs like Ozempic, with the regulator updating its advice around pregnancy and suicide. @Eliza_Rugg9 #9News pic.twitter.com/jLvg49sj87
— 9News Melbourne (@9NewsMelb) December 1, 2025
READ MORE AT DAILY MAIL
The Dennis Michael Lynch Podcast archive is available below, with the most recent on top. Never miss an episode. Subscribe to the show by downloading The DML News App or go to Apple Podcasts.
